Hogan Lovells 2024 Election Impact and Congressional Outlook Report
The reorganization aims to better align Myriad’s resources with domestic opportunities while continuing to serve key partnerships with biopharmaceutical companies and patients outside the United States.
Myriad Genetics is a leading company in genetic testing and precision medicine. The company develops and offers genetic tests that help assess the risk of developing disease or disease progression and support treatment decisions in medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.
Hogan Lovells team for Myriad Genetics
Germany
Peter Huber (Partner), Tobias Flasbarth (Counsel), Dr Patrick Waldecker, Dr Artem Vesdenetski, Shervin Mir Marashi (Associates) (Corporate/M&A);
Dr Anna-Katharina Friese-Okoro (Partner), Benedikt Dellen (Senior Associate), Dr Fabian Flüchter (Associate) (Intellectual Property);
Dr Ingmar Dörr (Partner, Tax);
Dr Tim Joppich (Partner), Dr Justus Frank (Counsel), Annika Weber (Senior Associate), Dr Jana Lind (Associate) (Employment);
Dr Christoph Wünschmann (Partner), Johanna Brock-Wenzek (Counsel) (Antitrust);
Netherlands
Alexander Fortuin (Partner), Matthijs Dols (Senior Associate), Vera Brouwer (Associate) (Tax);
Marieke Plaisier (Associate), Jamie Tang (Paralegal) (Corporate/M&A);
Belgium
Julius Jakob Gertz (Associate, Global Regulatory);
France
Marion Guertault (Partner), Hélène De Nazelle (Senior Associate), Cristina Sánchez Herrán, Axelle Galiniere (Associates) (Employment);
Beatrix H. Jahnel-Féret (Associate, Corporate/M&A);
UK
Eleanor Doubleday (Associate, Employment);
Australia
Charles Bogle (Partner, Corporate/M&A);
Stella Xi (Associate, Private Equity).